Outcomes of laparoscopic surgery in advanced gastric cancer patients who received neoadjuvant therapy represent a controversial issue. We performed an updated meta-analysis to evaluate the perioperative and long-term survival outcomes of laparoscopic gastrectomy (LG) versus conventional open gastrectomy (OG) in this subset of patients. Electronic databases including PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials and China National Knowledge Infrastructure were comprehensively searched up to May 2023. The short-term and long-term outcomes of LG versus OG in advanced gastric cancer patients undergoing neoadjuvant therapy were evaluated. Effect sizes with 95% confidence intervals were always assessed using random-effects model. The prospective protocol was registered with PROSPERO (CRD42022359126). Eighteen studies (2 randomized controlled trials and 16 cohort studies) involving 2096 patients were included. In total, 933 patients were treated with LG and 1163 patients were treated with OG. In perioperative outcomes, LG was associated with less estimated blood loss (MD = − 65.15; P < 0.0001), faster time to flatus (MD = − 0.56; P < 0.0001) and liquid intake (MD = − 0.42; P = 0.02), reduced hospital stay (MD = − 2.26; P < 0.0001), lower overall complication rate (OR = 0.70; P = 0.002) and lower minor complication rate (OR = 0.69; P = 0.006), while longer operative time (MD = 25.98; P < 0.0001). There were no significant differences between the two groups in terms of proximal margin, distal margin, R1/R2 resection rate, retrieved lymph nodes, time to remove gastric tube and drainage tube, major complications and other specific complications. In survival outcomes, LG and OG were not significantly different in overall survival, disease-free survival and recurrence-free survival. LG can be a safe and feasible technique for the treatment of advanced gastric cancer patients receiving neoadjuvant therapy. However, more high-quality randomized controlled trials are still needed to further validate the results of our study.
Objectives. Lotus leaf is rich in flavonoids, and this study is aimed at examining the inhibitory effect of lotus leaf‐enriched flavonoid extract (LLEFE) on HT‐29 colon cancer cells through phosphatidylinositol 3‐kinase/protein kinase B (PI3K/Akt) expression regulation. Methods. Lotus leaves were extracted by ethanol and purified using FL‐3 macroporous resin to create the LLEFE. HT‐29 colon cancer cells were tested using various methods: their proliferation was observed by 3‐(4,5)‐dimethylthiahiazo(‐z‐y1)‐3,5‐di‐phenytetrazoliumromide (MTT) assay, their survival status was observed by fluorescence staining, their oxidative stress level was observed by biochemical kits, and their mRNA expression was determined by quantitative polymerase chain reaction (qPCR) assay. Additionally, the composition of the flavonoids in lotus leaf was determined by HPLC. Results. The results showed that the proliferation of NCM460 normal human colon cells was not affected by 0–500 μg/mL LLEFE but the proliferation of HT‐29 human colon cancer cells decreased. LLEFE increased the LDH level in an HT‐29 colon cancer cell culture medium; also increased the superoxide dismutase (SOD), catalase (CAT) activities, and glutathione (GSH) level in HT‐29 cells; and decreased the malondialdehyde (MDA) level. Further experimental results showed that LLEFE upregulated the expression of SOD1, CAT, and GSH mRNA and downregulated the expression of PI3K, Akt, and mammalian target of rapamycin (mTOR) in HT‐29 cells. The high‐performance liquid chromatography (HPLC) results showed that kaempferin, hyperoside, astragaloside, phloridzin, and quercetin were the main chemical constituents of lotus leaf. Conclusion. Lotus leaves contain functional flavonoids that inhibit the proliferation of HT‐29 colon cancer cells and regulate the expression of PI3K/Akt through five important chemicals.
Background: Evidence suggests dMMR/MSI-H gastric cancer patients respond better to immune checkpoint inhibitors (ICIs) than to chemotherapy, but recent trials have not consistently shown this benefit in subgroup analyses. It remains unclear whether improved the pathological response translates into survival benefit. This study compares pathological response and survival outcomes between neoadjuvant immunotherapy regimens (ICI monotherapy, ICI plus chemotherapy, or dual ICIs; group A) and chemotherapy alone (group B) in locally advanced dMMR/MSI-H gastric cancer. Methods: Between January 2020 and December 2025, 24 patients undergoing surgery were enrolled—14 in group A and 10 in group B. The primary endpoints were major pathological response (MPR), pathological complete response (pCR), event-free survival (EFS), and overall survival (OS). A meta-analysis integrating our cohort with external studies was conducted to strengthen the evidence base. Results: In our cohort, compared with group B, group A appeared to have higher rates of MPR (85.7% vs. 20%) and pCR (42.9% vs. 0%). EFS and OS in group A improved numerically (EFS: p = 0.10; OS: p = 0.12). Surgical outcomes and treatment-related adverse events were not different between the two groups. Pooled analyses implied consistent improvements in MPR (RR = 4.09) and pCR (RR = 5.38). Additionally, reconstructed individual survival data suggested that group A might have better EFS (p = 0.034) while OS (p = 0.890) showed little difference. Conclusions: Neoadjuvant immunotherapy-based regimens might show some enhancements in treatment response rates and EFS compared with chemotherapy alone, which may imply their therapeutic potential in this molecularly defined patient population.
This article analyzes and explores the impact of standardized hand hygiene management for hospital patients and caregivers on reducing hospital infections. This article selects 50 clinical inpatients and nursing staff from a certain hospital in our district as the research subjects, and is randomly divided into OG (observation group) and CG (control group), with 25 people in each group. OG conducts standardized management of hand hygiene, while CG conducts routine care procedures. Compare the hand hygiene hospital infection status of two groups of patients and their caregivers. The results showed that out of 25 patients with CG, 12 (48%) developed hospital acquired infections. Among the 25 patients with OG, 4 (8%) developed hospital acquired infections. The hospital infection rate of OG was significantly lower than that of CG (P<0.05), and the qualified rate of hand hygiene testing among OG nursing staff was 84%, which was significantly higher than CG (52%). From this, it can be seen that standardized hand hygiene management for patients and their nursing staff has to some extent reduced the hospital infection rate, with good results and is worth promoting.